NCT02610413 Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
| NCT ID | NCT02610413 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute (NCI) |
| Condition | Breast Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 354 participants |
| Start Date | 2014-03-25 |
| Primary Completion | 2100-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 354 participants in total. It began in 2014-03-25 with a primary completion date of 2100-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.
Eligibility Criteria
Inclusion Criteria: * European American patients with deoxyribonucleic acid (DNA) available and designated case or control * Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab * Patients who did not develop hypertension following a full course of treatment with bevacizumab
Contact & Investigator
Bryan P Schneider
PRINCIPAL INVESTIGATOR
Eastern Cooperative Oncology Group
Frequently Asked Questions
Who can join the NCT02610413 clinical trial?
This trial is open to participants of all sexes, studying Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02610413 currently recruiting?
Yes, NCT02610413 is actively recruiting participants. Visit ClinicalTrials.gov or contact National Cancer Institute (NCI) to inquire about joining.
Where is the NCT02610413 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT02610413 clinical trial?
NCT02610413 is sponsored by National Cancer Institute (NCI). The principal investigator is Bryan P Schneider at Eastern Cooperative Oncology Group. The trial plans to enroll 354 participants.